R
Ricard Cervera
Researcher at University of Barcelona
Publications - 582
Citations - 49118
Ricard Cervera is an academic researcher from University of Barcelona. The author has contributed to research in topics: Antiphospholipid syndrome & Catastrophic antiphospholipid syndrome. The author has an hindex of 90, co-authored 537 publications receiving 42364 citations. Previous affiliations of Ricard Cervera include Benemérita Universidad Autónoma de Puebla.
Papers
More filters
Journal ArticleDOI
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
Spiros Miyakis,Michael D. Lockshin,Tatsuya Atsumi,D W Branch,Robin L. Brey,Ricard Cervera,R. H. W. M. Derksen,P. G. De Groot,Takao Koike,Pier Luigi Meroni,Guido Reber,Yehuda Shoenfeld,Angela Tincani,Panayiotis G. Vlachoyiannopoulos,Steven A. Krilis +14 more
TL;DR: This document appraise the existing evidence on clinical and laboratory features of APS addressed during the forum and proposes amendments to the Sapporo criteria, including definitions on features ofAPS that were not included in the updated criteria.
Journal ArticleDOI
Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
Ricard Cervera,J.C. Piette,Josep Font,Munther A. Khamashta,Yehuda Shoenfeld,María Teresa Camps,Søren Jacobsen,Gabriella Lakos,Angela Tincani,Irene Kontopoulou-Griva,Mauro Galeazzi,Pier Luigi Meroni,Ronald H. W. M. Derksen,Philip G. de Groot,Erika Gromnica-Ihle,Marta Baleva,Marta Mosca,Stefano Bombardieri,Frédéric Houssiau,Jean-Christophe Gris,Isabelle Quéré,Eric Hachulla,Carlos Vasconcelos,B. Roch,Antonio Fernández-Nebro,Marie Claire Boffa,Graham R. V. Hughes,Miguel Ingelmo +27 more
TL;DR: An association with SLE, the patient's sex, and the patient’s age at disease onset can modify the disease expression and define specific subsets of APS.
Journal ArticleDOI
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie,Michelle A. Petri,Omid Zamani,Ricard Cervera,Daniel J. Wallace,D. Tegzova,Jorge Sanchez-Guerrero,Andreas Schwarting,Joan T. Merrill,W. Winn Chatham,William Stohl,Ellen M. Ginzler,Douglas R. Hough,Z. John Zhong,William W. Freimuth,Ronald F van Vollenhoven +15 more
TL;DR: Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE.
Journal ArticleDOI
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients
Ricard Cervera,Munther A. Khamashta,Josep Font,Gian Domenico Sebastiani,Antonio Gil,Lavilla P,Juan Carlos Mejía,A. Olcay Aydintug,Hanna Chwalinska-Sadowska,Enrique de Ramón,Antonio Fernández-Nebro,Mauro Galeazzi,Merete Valen,Alessandro Mathieu,Frédéric Houssiau,Natividad Caro,Paula Alba,Manuel Ramos-Casals,Miguel Ingelmo,Graham R. V. Hughes +19 more
TL;DR: In this paper, the authors assessed the frequency and characteristics of the main causes of morbidity and mortality in systemic lupus erythematosus (SLE) during a 10-year period and compared the frequency of early manifestations with those that appeared later in the evolution of the disease.
Journal ArticleDOI
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Antonis Fanouriakis,Myrto Kostopoulou,Alessia Alunno,Martin Aringer,Ingeborg M. Bajema,John Boletis,Ricard Cervera,Andrea Doria,Caroline Gordon,Marcello Govoni,Frédéric Houssiau,David Jayne,Marios Kouloumas,Annegret Kuhn,Janni Lisander Larsen,Kirsten Lerstrøm,Gabriella Moroni,Marta Mosca,Matthias Schneider,Josef S Smolen,Elisabet Svenungsson,Vladimir Tesar,Angela Tincani,Anne Troldborg,Ronald F van Vollenhoven,Jörg Wenzel,George Bertsias,Dimitrios T. Boumpas +27 more
TL;DR: The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE, combining evidence-base and expert-opinion, based on emerging new evidence.